论文部分内容阅读
目的观察丹参酮ⅡA磺酸钠注射液治疗肺心病的疗效。方法120例肺心病急性加重期患者随机分为治疗组62例和对照组60例,两组均采用抗感染、平喘化痰、适当强心利尿及吸氧等常规治疗。治疗组在常规综合治疗的基础上加用丹参酮ⅡA磺酸钠注射液80mg加5%葡萄糖注射液250ml,静脉滴注,每日1次;对照组仅给予常规治疗,两组疗程均为2周。结果治疗组治疗后高切粘度、低切粘度、血浆粘度、红细胞聚集指数、红细胞比容、血小板聚集率与用药前比较,差异有统计学意义(P<0.05)。与对照组比较,以上各指标差异均有统计学意义(P<0.05)。治疗组临床总有效率及显效率分别88.3%及55.0%,对照组分别为70.0%及25.0%。治疗组疗效明显优于对照组(P<0.05)。治疗期间未见丹参酮ⅡA磺酸钠注射液引起的严重不良反应。结论丹参酮ⅡA磺酸钠注射液能显著改善慢性肺心病急性加重期患者的血液流变特性,故为辅助治疗肺心病的一种安全有效的药物。
Objective To observe the effect of tanshinone Ⅱ A sodium sulfonate injection on pulmonary heart disease. Methods A total of 120 patients with acute exacerbation of pulmonary heart disease were randomly divided into treatment group (n = 62) and control group (n = 60). Both groups were given conventional therapy such as anti-infective, antiasthmatic phlegm, proper cardiac diuresis and oxygen inhalation. The treatment group on the basis of conventional comprehensive treatment with tanshinone Ⅱ A sodium sulfonate injection 80mg plus 5% glucose injection 250ml, intravenous infusion, once daily; control group was given only conventional treatment, the two groups were treated for 2 weeks . Results After treatment, the high shear viscosity, low shear viscosity, plasma viscosity, erythrocyte aggregation index, hematocrit and platelet aggregation rate in the treatment group were significantly different from those before treatment (P <0.05). Compared with the control group, the above indexes had statistical significance (P <0.05). The total clinical effective rate and effective rate were 88.3% and 55.0% respectively in the treatment group and 70.0% and 25.0% in the control group respectively. The treatment group was significantly better than the control group (P <0.05). No serious side effects caused by tanshinone Ⅱ A sodium sulfonate injection were observed during the treatment. Conclusion Sodium tanshinone Ⅱ A sulfonate injection can significantly improve the blood rheology of patients with chronic cor pulmonale during acute exacerbation. Therefore, it is a safe and effective drug for adjuvant treatment of pulmonary heart disease.